These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24732039)

  • 21. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
    Costa RR; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Mendonça DVC; Freitas CS; Lage DP; Martins VT; Antinarelli LMR; Machado AS; Bandeira RS; Ludolf F; Santos TTO; Brito RCF; Humbert MV; Menezes-Souza D; Duarte MC; Chávez-Fumagalli MA; Roatt BM; Coimbra ES; Coelho EAF
    Med Microbiol Immunol; 2021 Jun; 210(2-3):133-147. PubMed ID: 33870453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis.
    Sane SA; Shakya N; Gupta S
    Exp Parasitol; 2011 Feb; 127(2):376-81. PubMed ID: 20846525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Th1-biased immunomodulation and therapeutic potential of Artemisia annua in murine visceral leishmaniasis.
    Islamuddin M; Chouhan G; Farooque A; Dwarakanath BS; Sahal D; Afrin F
    PLoS Negl Trop Dis; 2015 Jan; 9(1):e3321. PubMed ID: 25568967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
    Voak AA; Harris A; Coteron-Lopez JM; Angulo-Barturen I; Ferrer-Bazaga S; Croft SL; Seifert K
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009013. PubMed ID: 33651812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
    Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
    J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reciprocal changes in CD11c
    Yadav PK; Chandrakar P; Sharma P; Vishwakarma P; Parmar N; Srivastava M; Kar S
    Vaccine; 2020 Jan; 38(2):355-365. PubMed ID: 31648908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model.
    Carvalho LM; Gusmão MR; Costa AFP; de Brito RCF; Aguiar-Soares RDO; Cardoso JMO; Reis AB; Carneiro CM; Roatt BM
    Parasitology; 2022 Mar; 149(3):371-379. PubMed ID: 35264268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.
    Palić S; Bhairosing P; Beijnen JH; Dorlo TPC
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.
    Hendrickx S; Bulté D; Van den Kerkhof M; Cos P; Delputte P; Maes L; Caljon G
    Int J Parasitol Drugs Drug Resist; 2019 Apr; 9():1-7. PubMed ID: 30562667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis.
    Dias ÁFLR; Ayres EDCBS; de Oliveira Martins DT; Maruyama FH; de Oliveira RG; de Carvalho MR; Almeida ADBPF; Teixeira ALS; Mendonça AJ; Sousa VRF
    Exp Parasitol; 2020 Oct; 217():107947. PubMed ID: 32628971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.
    Murray HW
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3235-6. PubMed ID: 11036063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
    Gangalum PR; de Castro W; Vieira LQ; Dey R; Rivas L; Singh S; Majumdar S; Saha B
    J Immunol; 2015 Jun; 194(12):5961-7. PubMed ID: 25980013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
    Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
    J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
    Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis.
    Shakya N; Sane SA; Shankar S; Gupta S
    Peptides; 2011 Oct; 32(10):2131-3. PubMed ID: 21959258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lupeol and amphotericin B mediate synergistic anti-leishmanial immunomodulatory effects in Leishmania donovani-infected BALB/c mice.
    Das A; Jawed JJ; Das MC; Parveen S; Ghosh C; Majumdar S; Saha B; Bhattacharjee S
    Cytokine; 2021 Jan; 137():155319. PubMed ID: 33002744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoprotective effect of lentinan in combination with miltefosine on Leishmania-infected J-774A.1 macrophages.
    Shivahare R; Ali W; Singh US; Natu SM; Khattri S; Puri SK; Gupta S
    Parasite Immunol; 2016 Oct; 38(10):618-27. PubMed ID: 27387601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
    Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis.
    Das S; Rani M; Rabidas V; Pandey K; Sahoo GC; Das P
    Br J Pharmacol; 2014 Mar; 171(5):1260-74. PubMed ID: 24670148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
    Banerjee A; De M; Ali N
    J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.